120 related articles for article (PubMed ID: 9406710)
1. Imaging for improved prediction of myelotoxicity after radioimmunotherapy.
DeNardo DA; DeNardo GL; O'Donnell RT; Lim SM; Shen S; Yuan A; DeNardo SJ
Cancer; 1997 Dec; 80(12 Suppl):2558-66. PubMed ID: 9406710
[TBL] [Abstract][Full Text] [Related]
2. Overview of radiation myelotoxicity secondary to radioimmunotherapy using 131I-Lym-1 as a model.
DeNardo GL; DeNardo SJ; Macey DJ; Shen S; Kroger LA
Cancer; 1994 Feb; 73(3 Suppl):1038-48. PubMed ID: 8306246
[TBL] [Abstract][Full Text] [Related]
3. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.
Lim SM; DeNardo GL; DeNardo DA; Shen S; Yuan A; O'Donnell RT; DeNardo SJ
J Nucl Med; 1997 Sep; 38(9):1374-8. PubMed ID: 9293790
[TBL] [Abstract][Full Text] [Related]
4. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy.
Wilder RB; DeNardo GL; Sheri S; Fowler JF; Wessels BW; DeNardo SJ
Eur J Nucl Med; 1996 Aug; 23(8):953-7. PubMed ID: 8753685
[TBL] [Abstract][Full Text] [Related]
5. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
Behr TM; Béhé M; Sgouros G
Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
[TBL] [Abstract][Full Text] [Related]
6. Prediction of myelotoxicity using semi-quantitative marrow image scores.
Lim S; DeNardo GL; DeNardo DA; O'Donnell RT; Yuan A; DeNardo SJ
J Nucl Med; 1997 Nov; 38(11):1749-53. PubMed ID: 9374345
[TBL] [Abstract][Full Text] [Related]
7. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake.
Juweid M; Sharkey RM; Siegel JA; Behr T; Goldenberg DM
Cancer Res; 1995 Dec; 55(23 Suppl):5827s-5831s. PubMed ID: 7493354
[TBL] [Abstract][Full Text] [Related]
8. Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.
Denardo GL; Denardo SJ; Kukis DL; O'Donnell RT; Shen S; Goldstein DS; Kroger LA; Salako Q; Denardo DA; Mirick GR; Mausner LF; Srivastava SC; Meares CF
Anticancer Res; 1998; 18(4B):2779-88. PubMed ID: 9713461
[TBL] [Abstract][Full Text] [Related]
9. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.
Macey DJ; DeNardo SJ; DeNardo GL; DeNardo DA; Shen S
Clin Nucl Med; 1995 Feb; 20(2):117-25. PubMed ID: 7720301
[TBL] [Abstract][Full Text] [Related]
10. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.
O'Donnell RT; Shen S; Denardo SJ; Wun T; Kukis DL; Goldstein DS; Denardo GL
Anticancer Res; 2000; 20(5C):3647-55. PubMed ID: 11268433
[TBL] [Abstract][Full Text] [Related]
12. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
Shen S; Meredith RF; Duan J; Macey DJ; Khazaeli MB; Robert F; LoBuglio AF
J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
[TBL] [Abstract][Full Text] [Related]
13. A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Carr CE; Mirick GR; DeNardo SJ
J Nucl Med; 1999 Dec; 40(12):2014-20. PubMed ID: 10616879
[TBL] [Abstract][Full Text] [Related]
14. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies.
Juweid ME; Zhang CH; Blumenthal RD; Hajjar G; Sharkey RM; Goldenberg DM
J Nucl Med; 1999 Oct; 40(10):1609-16. PubMed ID: 10520699
[TBL] [Abstract][Full Text] [Related]
15. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
[TBL] [Abstract][Full Text] [Related]
16. Correlation of marrow dose estimates based on serial pretreatment radiopharmaceutical imaging and blood data with actual marrow toxicity in anti-CD20 yttrium-90 monoclonal antibody radioimmunotherapy of non-Hodgkin's B-cell lymphoma.
Erwin WD; Spies SM; Kelly ME; Rao P; Eckersberg-Rhodes TE; Nannapaneni M; Groch MW
Nucl Med Commun; 2001 Feb; 22(2):247-55. PubMed ID: 11258413
[TBL] [Abstract][Full Text] [Related]
17. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
18. Studies on the red marrow dosimetry in radioimmunotherapy: an experimental investigation of factors influencing the radiation-induced myelotoxicity in therapy with beta-, Auger/conversion electron-, or alpha-emitters.
Behr TM; Sgouros G; Stabin MG; Béhé M; Angerstein C; Blumenthal RD; Apostolidis C; Molinet R; Sharkey RM; Koch L; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3031s-3043s. PubMed ID: 10541340
[TBL] [Abstract][Full Text] [Related]
19. Personalized dosimetry of 131I-rituximab radioimmunotherapy of non-hodgkin lymphoma defined by pharmacokinetics in bone marrow and blood.
Boucek JA; Turner JH
Cancer Biother Radiopharm; 2014 Feb; 29(1):18-25. PubMed ID: 24134141
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
Behr TM; Sharkey RM; Juweid ME; Dunn RM; Vagg RC; Ying Z; Zhang CH; Swayne LC; Vardi Y; Siegel JA; Goldenberg DM
J Nucl Med; 1997 Jun; 38(6):858-70. PubMed ID: 9189130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
